证券代码：688117 证券简称：圣诺生物 公告编号：2026-003 成都圣诺生物科技股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以成都圣诺生物 科技股份有限公司（以下简称"公司"）2025年年度报告为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位：人民币元 ■ 3、影响经营业绩的主要因素 报告期内，公司持续专注于主营业务多肽药物CDMO、原料药和制剂的协同发展，得益于全球多肽药物 市场降糖、减重领域的药品需求持续放量，使得公司GLP-1原料药销量大增，经营业绩大幅提升。 （二）上表中有关项目增减变动幅度达30%以上的主要原因 注：1.本报告期初数同法定披露的上年年末数。 2.表中财务数据及指标均以合并报表数据填列，但未经审计，最终结果以公司2025年年度报告为准；表 中增减变动幅度数据如有尾差，系四舍五入所致。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况、财务状 ...

Core Viewpoint - Metformin, a long-established diabetes medication, is often referred to as a "miracle drug" due to its potential benefits beyond blood sugar control, including weight loss, anti-aging effects, and possible anti-cancer properties [1][2][3][4]. Summary by Sections Metformin's Primary Use - Metformin has been used for over 60 years as a first-line oral medication for type 2 diabetes, effectively lowering blood sugar levels by reducing liver glucose output and improving insulin resistance, with an average reduction in glycated hemoglobin of 1.0% to 1.5% [2][4]. Additional Benefits - Recent studies suggest that metformin may provide additional benefits, such as weight loss of approximately 3 kg in overweight or obese diabetic patients through appetite suppression and increased satiety, although it is not a weight loss drug [2][3]. - Metformin may reduce the risk of cardiovascular events like myocardial infarction and stroke by about 27%, potentially due to its effects on insulin resistance, inflammation, and endothelial function [3]. - In metabolic syndrome management, metformin can improve insulin resistance and may assist with lipid levels and fatty liver disease [3]. - Some observational studies indicate that metformin use in diabetic patients may lower the risk of certain cancers, such as breast and colorectal cancer, although it is not a standard cancer treatment [3]. - There are indications that metformin might reduce the incidence of age-related diseases, but the mechanisms and long-term safety are not fully understood [3]. Safety and Usage Guidelines - Metformin is considered a relatively safe and effective medication, but it should not be viewed as a "miracle drug." Its use must be based on clear medical indications and under professional guidance [4]. - Common side effects include gastrointestinal discomfort and vitamin B12 deficiency, which can lead to anemia or neuropathy if not monitored [6]. - Metformin is primarily indicated for type 2 diabetes, type 1 diabetes, polycystic ovary syndrome with insulin resistance, and high-risk diabetic populations [5].

Core Viewpoint - A product named "Ginseng Bitter Melon Buckwheat Mulberry Leaf Tablets" is being marketed as a "sugar-lowering miracle drug" on various online platforms, particularly targeting elderly individuals with high blood sugar and diabetes, despite lacking scientific backing for its claims [1][4]. Group 1: Product Marketing and Claims - The product is heavily promoted on short video platforms, with influencers and AI hosts endorsing its benefits without clearly stating its intended use [1]. - Customer service representatives from various platforms claim that the product can help regulate blood sugar levels, but the actual product descriptions often avoid direct claims of medical efficacy [4][6]. - Many customer reviews suggest that users are treating the product as a substitute for diabetes medication, indicating a misunderstanding of its actual purpose [4]. Group 2: Regulatory and Safety Concerns - The product is classified as a food item rather than a health supplement or medication, which means it does not have the necessary regulatory approval for health claims [5]. - The marketing strategies employed by sellers often skirt around legal restrictions on advertising health benefits, leading to vague and misleading statements [6]. - Ingredients such as maltodextrin and glucose, which are present in the product, can actually raise blood sugar levels, contradicting the claims of being a "sugar-lowering" product [7][10]. Group 3: Expert Opinions and Scientific Evidence - Experts indicate that while some ingredients like ginseng and bitter melon may have potential benefits for blood sugar regulation, they are not effective in the concentrations found in these products [10][11]. - The low concentration of active ingredients raises questions about the product's efficacy, as the beneficial components are present in negligible amounts [10]. - It is emphasized that these products should not replace conventional diabetes treatments, and consumers should be cautious of misleading claims that could delay proper medical care [11].

Core Viewpoint - A product named "Ginseng Bitter Melon Buckwheat Mulberry Leaf Tablets" is being marketed as a "sugar-lowering miracle drug" on various online platforms, particularly targeting elderly individuals with high blood sugar and diabetes, despite lacking scientific backing for such claims [1][4][5]. Group 1: Product Marketing and Claims - The product is heavily promoted on short video platforms, with influencers and AI hosts endorsing its benefits without clearly stating its intended use [1][4]. - Customer service representatives from various platforms claim that the product can help regulate blood sugar levels, but these claims are often vague and avoid direct references to medical benefits [4][5]. - Many customer reviews suggest that users are treating the product as a substitute for diabetes medication, indicating a misunderstanding of its actual purpose [4][6]. Group 2: Regulatory and Safety Concerns - The product is classified as a food item rather than a health supplement or medication, which means it cannot legally claim to treat or prevent diseases [5][6]. - The ingredients listed in the product, such as glucose and maltodextrin, are known to raise blood sugar levels, contradicting its marketed benefits [6][8]. - Experts warn that while some ingredients may have potential health benefits, the product's formulation does not provide sufficient active ingredients to achieve any therapeutic effect [8][9]. Group 3: Expert Opinions - Experts emphasize that while certain ingredients like mulberry leaves and bitter melon may have some blood sugar-lowering properties, they should not replace conventional diabetes treatments [9]. - The low concentration of active ingredients in the product raises questions about its efficacy, with experts noting that the claims made by marketers could be misleading [8][9].

Core Viewpoint - Rhine Biotech is undergoing a change in control, with the majority of shares being transferred to Guangzhou Defu Nutrition Investment Partnership, while simultaneously planning to acquire at least 80% of Beijing Jinkangpu Food Technology Co., Ltd. [2][4] Group 1: Control Change and Acquisition - Rhine Biotech's controlling shareholder, Qin Benjun, will transfer part of his shares to Guangzhou Defu Nutrition, which will become the new controlling shareholder [2][4] - The acquisition involves purchasing at least 80% of Beijing Jinkangpu's shares, which is expected to enhance Rhine Biotech's competitiveness in the food and health product sectors [6][7] Group 2: Financial Performance and Market Position - Rhine Biotech, known as the "King of Sugar" in China, reported a revenue of approximately 1.272 billion yuan for the first three quarters of the year, reflecting a year-on-year growth of 8.73%, but faced a net profit decline of 30.73% to about 70.4 million yuan due to intense market competition [6] - The sweetener market is showing signs of stagnation, impacting Rhine Biotech's profitability despite revenue growth [6] Group 3: Financial Challenges and Regulatory Issues - The company is under financial pressure, with a significant portion of Qin Benjun's shares pledged, amounting to approximately 1.77 billion shares, representing a pledge ratio of 65.13% [8][9] - Regulatory scrutiny has increased, with the company facing a fine of 600,000 yuan due to a production safety incident and other compliance issues [9]

Group 1 - The core viewpoint of the report is that Guotai Junan Securities has given a "buy" rating for China Resources Sanjiu (000999.SZ) based on its strategic positioning in weight loss and blood sugar reduction markets, as well as the promising clinical progress of BGM0504 injection [2] - The collaboration with Borui Pharmaceutical is highlighted as a strong partnership that will enhance product development and share sales results, indicating a synergistic effect on the company's growth [2] - The company is noted for its strong commercialization capabilities, with BGM0504 injection expected to become an important addition to its product pipeline, which could drive future revenue growth [2]